These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 16820901)
1. Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2. Hakozaki M; Hojo H; Sato M; Kaneko Y; Watanabe N; Kikuchi S; Abe M Oncol Rep; 2006 Aug; 16(2):265-71. PubMed ID: 16820901 [TBL] [Abstract][Full Text] [Related]
2. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors. Uno K; Takita J; Yokomori K; Tanaka Y; Ohta S; Shimada H; Gilles FH; Sugita K; Abe S; Sako M; Hashizume K; Hayashi Y Genes Chromosomes Cancer; 2002 May; 34(1):33-41. PubMed ID: 11921280 [TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2. Hakozaki M; Hojo H; Sato M; Tajino T; Yamada H; Kikuchi S; Abe M Anticancer Res; 2006; 26(5A):3393-401. PubMed ID: 17094458 [TBL] [Abstract][Full Text] [Related]
4. Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Kuroda H; Moritake H; Sawada K; Kuwahara Y; Imoto I; Inazawa J; Sugimoto T Cancer Genet Cytogenet; 2005 Apr; 158(2):172-9. PubMed ID: 15796965 [TBL] [Abstract][Full Text] [Related]
5. Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1). Hakozaki M; Hojo H; Kikuchi S; Abe M Oncol Rep; 2007 Jan; 17(1):169-73. PubMed ID: 17143495 [TBL] [Abstract][Full Text] [Related]
6. Rhabdoid tumor of the kidney is a component of the rhabdoid predisposition syndrome. Lee HY; Yoon CS; Sevenet N; Rajalingam V; Delattre O; Walford NQ Pediatr Dev Pathol; 2002; 5(4):395-9. PubMed ID: 12016529 [TBL] [Abstract][Full Text] [Related]
7. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Biegel JA; Tan L; Zhang F; Wainwright L; Russo P; Rorke LB Clin Cancer Res; 2002 Nov; 8(11):3461-7. PubMed ID: 12429635 [TBL] [Abstract][Full Text] [Related]
8. The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. Albanese P; Belin MF; Delattre O Eur J Cancer; 2006 Sep; 42(14):2326-34. PubMed ID: 16908131 [TBL] [Abstract][Full Text] [Related]
9. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Caramel J; Medjkane S; Quignon F; Delattre O Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027 [TBL] [Abstract][Full Text] [Related]
11. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features. Cho YM; Choi J; Lee OJ; Lee HI; Han DJ; Ro JY Pathol Int; 2006 Nov; 56(11):702-6. PubMed ID: 17040295 [TBL] [Abstract][Full Text] [Related]
12. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. DeCristofaro MF; Betz BL; Wang W; Weissman BE Oncogene; 1999 Dec; 18(52):7559-65. PubMed ID: 10602515 [TBL] [Abstract][Full Text] [Related]
13. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Versteege I; Sévenet N; Lange J; Rousseau-Merck MF; Ambros P; Handgretinger R; Aurias A; Delattre O Nature; 1998 Jul; 394(6689):203-6. PubMed ID: 9671307 [TBL] [Abstract][Full Text] [Related]
14. Novel germ-line deletion of SNF5/INI1/SMARCB1 gene in neonate presenting with congenital malignant rhabdoid tumor of kidney and brain primitive neuroectodermal tumor. Kusafuka T; Miao J; Yoneda A; Kuroda S; Fukuzawa M Genes Chromosomes Cancer; 2004 Jun; 40(2):133-9. PubMed ID: 15101046 [TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of malignant rhabdoid tumor of the kidney. Kinoshita Y; Tamiya S; Oda Y; Mimori K; Inoue H; Ohta S; Tajiri T; Suita S; Tsuneyoshi M Oncol Rep; 2001; 8(1):43-8. PubMed ID: 11115567 [TBL] [Abstract][Full Text] [Related]
16. Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Frühwald MC; Hasselblatt M; Wirth S; Köhler G; Schneppenheim R; Subero JI; Siebert R; Kordes U; Jürgens H; Vormoor J Pediatr Blood Cancer; 2006 Sep; 47(3):273-8. PubMed ID: 16206192 [TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization. Medjkane S; Novikov E; Versteege I; Delattre O Cancer Res; 2004 May; 64(10):3406-13. PubMed ID: 15150092 [TBL] [Abstract][Full Text] [Related]
18. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Chai J; Charboneau AL; Betz BL; Weissman BE Cancer Res; 2005 Nov; 65(22):10192-8. PubMed ID: 16288006 [TBL] [Abstract][Full Text] [Related]
19. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. Bourdeaut F; Fréneaux P; Thuille B; Lellouch-Tubiana A; Nicolas A; Couturier J; Pierron G; Sainte-Rose C; Bergeron C; Bouvier R; Rialland X; Laurence V; Michon J; Sastre-Garau X; Delattre O J Pathol; 2007 Feb; 211(3):323-30. PubMed ID: 17152049 [TBL] [Abstract][Full Text] [Related]
20. No evidence for hypermethylation of the hSNF5/INI1 promoter in pediatric rhabdoid tumors. Zhang F; Tan L; Wainwright LM; Bartolomei MS; Biegel JA Genes Chromosomes Cancer; 2002 Aug; 34(4):398-405. PubMed ID: 12112529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]